Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain

Keyphrases

• Attenuation 100%
• Vaccine Strain 100%
• Rift Valley Fever Virus 100%
• Protective Efficacy 100%
• Live Attenuated 66%
• Rift Valley Fever 66%
• Ruminants 66%
• M Segment 66%
• S Segment 66%
• Silent mutation 66%
• Vaccination 33%
• Virulence 33%
• Recombinant 33%
• Sheep 33%
• Reassortant 33%
• Mosquito-borne 33%
• Cattle 33%
• Immunogenic 33%
• Zoonotic Disease 33%
• Africa 33%
• Rift Valley Fever Vaccine 33%
• Endemic Countries 33%
• MP-12 Vaccine 33%
• Titer 33%
• Camel 33%
• Plaque Reduction Neutralization Test 33%
• Goat 33%
• Genetic Markers 33%
• Vulnerable Populations 33%
• Arabian Peninsula 33%
• Codon Usage 33%
• Outbred Mice 33%
• Attenuated Strain 33%
• RVFV Vaccine 33%
• Reassortant Strain 33%
• Attenuation Profiles 33%
• Codon Pair Bias 33%

Immunology and Microbiology

• Vaccine Efficacy 100%
• Rift Valley Fever 100%
• Phlebovirus 100%
• Reassortment 50%
• Rift Valley Fever Virus 50%
• Silent Mutation 50%
• Vaccination Policy 25%
• Wild Type 25%
• Titer 25%
• Bovine 25%
• Zoonosis 25%
• Genetic Marker 25%
• Codon 25%
• Camel 25%
• Plaque Reduction Neutralization Test 25%
• Codon Usage 25%
• Outbred Mouse Strain 25%
• Vulnerable Population 25%